GKOS
What one share of GLAUKOS holds
Surgical and Medical Instruments and Apparatus
Glaukos is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal disease.
GLAUKOS’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $10.58 |
|---|---|
| Profit | −$3.25 |
| Capex (buildings and equipment) | $0.19 |
| Free cash flow | −$0.21 |
| Cash and investments | $1.95 |
| Book value | $11.60 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2013 | $10.29 | −$6.21 | $0.42 | −$6.95 | — | −$73.20 |
| 2014 | $19.87 | −$5.29 | $0.38 | −$3.48 | — | −$61.96 |
| 2015 | $4.10 | −$2.13 | $0.05 | −$0.18 | — | $2.96 |
| 2016 | $3.14 | $0.12 | $0.17 | $0.17 | — | $3.46 |
| 2017 | $4.63 | −$0.00 | $0.18 | $0.58 | — | $3.99 |
| 2018 | $5.13 | −$0.37 | $0.29 | $0.24 | — | $4.82 |
| 2019 | $5.76 | $0.37 | $0.11 | −$0.12 | — | $15.48 |
| 2020 | $5.06 | −$2.70 | $0.16 | −$0.67 | — | $14.75 |
| 2021 | $6.33 | −$1.07 | $1.03 | −$0.50 | — | $12.50 |
| 2022 | $5.96 | −$2.09 | $0.64 | −$1.34 | — | $11.10 |
| 2023 | $6.50 | −$2.78 | $0.42 | −$1.61 | — | $9.40 |
| 2024 | $7.27 | −$2.77 | $0.12 | −$1.28 | — | $13.59 |
| 2025 | $8.87 | −$3.28 | $0.13 | −$0.39 | — | $11.41 |